Lilly's breast cancer drug combination succeeds key study

By Natalie Grover
(Reuters) – Eli Lilly and Co’s combination of its experimental breast cancer drug and another widely used treatment slowed disease progression in patients who relapsed or did not benefit enough when treated with the anti-estrogen therapy.
In August, an independent data monitoring committee recommended the late-stage study continue without modification, even though interim evaluation suggested the combination treatment was not delaying cancer progression.
Lilly&rsqu